Home › Prostate Cancer › NCT03620786
HIFU for Focal Ablation of Prostate Tissue: An Observational Study
High-Intensity Focused Ultrasound for Focal Ablation of Prostate Tissue: An Observational Study of Multiparametric MRI and Ultrasound Fusion Imaging for Guidance
Who can join
Ages 40 to 85 · Men
Full eligibility criteria
Inclusion Criteria: 1. Age 40 years to 85 years 2. Subject has elected or already undergone HIFU therapy as their standard of care treatment methodand declined alternative treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy) 3. PSA ≤ 20 4. Prostate volume of ≤ 70 cc 5. Ability to complete informed consent form Exclusion Criteria: 1. Prior treatment for prostate cancer (with the exception of androgen deprivation therapy) 2. Medical contraindication to follow-up mpMRI or prostate biopsy 3. Unable to tolerate general or regional anesthesia 4. Positive bone scan (only if bone scan has been done or clinically indicated. Bone scan does not need to be performed for study eligibility determination.)
About the study
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.
What is being tested
- Sonablate HIFU device (device)
Sponsor: University of California, Los Angeles · Participants: 100 · Started: Sep 26, 2018
Contact the study team
- Michelle C Cardenas, MSN, NP · Phone: (310) 794-3070
- Ankush sachdeva · Phone: 310-794-7700
Official record on ClinicalTrials.gov — NCT03620786
Locations in the U.S.
| California | University of California, Los Angeles, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.